Pinnacle Clinical Research Welcomes Jubilee to Its Family
Pinnacle Clinical Research Welcomes Jubilee to Its Family
LongueVue Capital (LVC) is excited to share that its portfolio company, Pinnacle Clinical Research, has recently broadened its capabilities through the acquisition of Jubilee Clinical Research, Inc. This move marks a significant development as Pinnacle continues to position itself as a leader in clinical trial site organizations, particularly focusing on metabolic and cardiovascular diseases.
Strategic Growth Through Acquisition
Pinnacle has established itself firmly in the clinical trial arena since its inception. With the acquisition of Jubilee, founded in 2017 by Dr. Elliot Shin, Pinnacle effectively enhances its reach and expertise in managing complex trials. Jubilee, recognized for its solid operational focus on metabolic and cardiovascular clinical trials, brings valuable assets and knowledge that complement Pinnacle’s existing portfolio.
Strengthening Expertise in Therapeutic Areas
The integration of Jubilee into Pinnacle allows the company to embark on new therapeutic horizons. Jubilee’s specialized knowledge will work in tandem with Pinnacle’s established infrastructures, cultivating new pharmaceutical relationships and advancing patient care. Dr. Shin’s commitment to delivering high-quality patient management translates seamlessly into Pinnacle's overarching mission.
A United Vision for Clinical Excellence
Ryan Nagim, Managing Partner at LVC, emphasized the importance of this acquisition in strengthening Pinnacle’s network. Expressing his enthusiasm, he mentioned, "Jubilee is an excellent addition to the Pinnacle network as it expands both our geographic presence and therapeutic area expertise." This acquisition is the seventh to be made by LVC to support Pinnacle’s expansion, showcasing LVC’s dedication to scaling operations effectively.
Commitment to Patient Care
Dr. Elliot Shin voiced his excitement about joining forces with Pinnacle, highlighting his admiration for Pinnacle's founder, Dr. Stephen Harrison. Shin looks forward to enhancing Jubilee’s offerings under the Pinnacle banner, ensuring that patients in the region receive exemplary care backed by advanced resource capabilities. This partnership promises to deliver exceptional outcomes in clinical trials.
About Jubilee Clinical Research
Jubilee Clinical Research stands out as a multi-therapeutic site concentrating on complex clinical trials, specifically in metabolic diseases and cardiovascular health. The organization’s focus on innovative treatment methodologies relates closely to the growing demand for specialized research in areas such as metabolic-associated liver diseases, cholesterol control, and diabetes treatments. Bedroomed by an expert team, Jubilee emphasizes patient recruitment and community engagement, fostering trust and reliability in clinical trial execution.
About Pinnacle Clinical Research
Pinnacle Clinical Research operates as a leading site management organization, boasting a network of 15 sites nationwide. Its commitment to executing sophisticated clinical trials is evident through its focus on metabolic and central nervous system disorders. With a strong physician team at the helm, Pinnacle works diligently to develop pioneering treatments that address the needs of underserved populations, ensuring not only scientific advancement but also compassionate patient care.
About LongueVue Capital
LongueVue Capital, established in 2001, operates from a foundation of over 20 years of successful partnerships with entrepreneurs and management teams. The firm specializes in providing transformational growth capital to middle-market businesses, leveraging its substantial experience and dedicated approach to value creation. With a portfolio that includes over $1 billion in committed capital across five funds, LVC showcases its capacity to drive substantial growth while maximizing stakeholder value.
Frequently Asked Questions
What is the recent acquisition by Pinnacle Clinical Research?
Pinnacle Clinical Research has acquired Jubilee Clinical Research, enhancing its capabilities in complex clinical trials.
Who founded Jubilee Clinical Research?
Jubilee Clinical Research was founded by Dr. Elliot Shin in 2017, specializing in metabolic and cardiovascular clinical trials.
How does this acquisition benefit Pinnacle's operations?
The acquisition strengthens Pinnacle’s therapeutic expertise and geographic presence in the clinical research community.
What areas does Jubilee focus on?
Jubilee emphasizes research in metabolic diseases, cardiovascular conditions, and advanced treatments for diabetes and obesity.
What is LongueVue Capital's role in this acquisition?
LongueVue Capital facilitated the acquisition, showcasing its commitment to scaling Pinnacle through strategic partnerships and investments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- A Comprehensive Look at America's Economic Challenges Today
- Supermicro Faces Challenges Amid DOJ Probe and Stock Split
- Eljona Shkreli Appointed as New Managing Director at Stratus
- Leadership Transition at Octagon Credit Investors Announced
- Investigation Launched into 2seventy bio, Inc.: What You Need to Know
- Impact of 'City of Dreams' and Its Commitment to Anti-Trafficking
- CoinFund Expands Investment Team Amid Rising Crypto Trends
- Rising Neutral Sentiment Signals Caution Among Investors
- PIMCO Global StocksPLUS (PGP) Soars to 52-Week High at $8.32
- China's Innovative Transformation of Kubuqi Desert to Solar Power
Recent Articles
- Celebrating a Century: Van Leeuwen Earns Royal Designation
- York Space Systems Unveils Significant Advances in Satellite Tech
- Mercy Executive Recognized Among Top AI Leaders Nationwide
- Groundbreaking Combination Therapy Achieves Remarkable Results
- The Mother Hips Unveil Their New Album 'California Current'
- Avantor to Announce Q3 2024 Earnings and Host Conference Call
- Innovative TALVEY® and TECVAYLI® Combination Shows Promise
- Why Wall Street Analysts Recommend Selling Palantir Stock
- Top Vanguard ETFs for Steady Income and Growth Potential
- The Growing Landscape of Refurbished Laboratory Equipment
- TGS ASA Receives Ba3 Rating Upgrade from Moody’s Agency
- The Enchantment of Shadowdock: Belfast Celebrates History
- Beyond Air Solidifies Financial Position with New Loan Agreement
- Innovative LungFit® PH System Delivers Care at U.S. Naval Hospital
- Kamala Harris: A New Direction for Cryptocurrency Regulation?
- NPCI International Partners to Advance Digital Payments in Caribbean
- Harris Gains Ground on Trump in Critical Swing States Race
- Projected ECB Rate Cuts Spark Market Anticipation
- Morgan Stanley Downgrades Udemy: What This Means for Investors
- Mining Firms Face Valuation Challenges During Copper Demand Shift
- Spotting Top Growth Stocks: Schlumberger and ACI Worldwide Insights
- Market Anticipation Builds Ahead of Key Inflation Data Release
- Diving into the Future of the Polymeric Membrane Market
- Exploring the Future of Fintech Software from 2024 Onwards
- Beyond Air Strengthens Financial Position Through New Offering
- Venus Concept Transforms Debt to Equity for Financial Strength
- Sparton Resources Expands Into Renewable Energy Market
- HPQ Silicon Achieves Key Milestone in Fumed Silica Reactor
- Beyond Air Restructures Debt to Boost Financial Stability
- Beyond Air Enhances Neonatal Care with LungFit® PH Delivery
- Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025
- Mizuho Securities Bullish on Xcel Energy's Future Plans
- Citi Upgrades Vipshop with New Price Target and Buy Rating
- SciBase's Nevisense Device Sold to NIH: A New Era in Dermatology
- CIMC Enric and Angang Steel Launch Innovative Hydrogen Project
- Boston Scientific's FARAPULSE System Approved in Japan
- Zula Casino Celebrates One Year with Unforgettable Promotions
- Intuit Inc. Targets Growth with Strategic AI Integration
- Uranium Energy Corp Reports Transformative Fiscal Year Gains
- Significant Milestone for Regeneron with Dupixent Approval in China
- SciBase's Strategic Move: Nevisense Now Under NIH Research
- Tonix Pharmaceuticals: New Patent and Future Prospects Ahead
- Invisors Celebrated among Top Workplaces for 2024
- Establishment Labs' FDA Approval Sparks Investor Optimism
- Invisors Awarded as Top Workplace in Consulting Sector
- Establishment Labs Gains Momentum After FDA Approval of Implants
- Benitec BioPharma Upscale: Evaluating Future Prospects
- Goldman Sachs Boosts Westlife Foodworld's Stock Outlook Significantly
- Rising Expectations for October ECB Rate Cuts Amid Soft Inflation
- Meta Faces Significant EU Fine for Password Mismanagement